StockData
Capricor Therapeutics, Inc. logo

Capricor Therapeutics, Inc. (CAPR) stock

CAPRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 6/30
$8.41+0.11 (+1.33%)

Close on Nov 17, 2026Market cap $488.95MP/E –Yield –

Capricor Therapeutics price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Capricor Therapeutics's price to sales ratio was 26.0× on Apr 30, 2025, against 6.5× a year earlier. Over the last 5 years it ranged from 3.7× to 407.2×, with a median of 24.0×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2025Apr 30, 202526.0×+2.0
2024Dec 31, 202424.0×+15.0
2023Dec 29, 20239.0×−304.1
2022Apr 29, 2022313.1×+79.3
2021Dec 31, 2021233.7×+87.6
2020Dec 31, 2020146.1×+142.4
2019Dec 31, 20193.7×−4.7
2018Dec 31, 20188.4×−4.4
2017Dec 29, 201712.8×−0.7
2016Dec 30, 201613.5×+4.9
2015Dec 31, 20158.6×−4.4
2014Dec 31, 201413.0×−53.2
2013Dec 31, 201366.1×+1.3
2012Dec 31, 201264.8×–

More Capricor Therapeutics figures

See a number that looks wrong?